DEF 14A: Silexion Therapeutics Seeks Shareholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

Silexion Therapeutics is asking shareholders to approve a reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement.

Summary

• Silexion Therapeutics is holding an extraordinary general meeting on November 12, 2024, to seek shareholder approval for a reverse share split.
• The proposed reverse share split would be at a ratio of not less than 1-for-10 and not more than 1-for-20, with the exact ratio to be determined by the board of directors prior to the meeting.
• The primary reason for the reverse share split is to maintain compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share.
• The company's board will determine the specific reverse split ratio based on market conditions and the market price of the ordinary shares leading up to the meeting.
• The reverse share split will decrease the number of outstanding ordinary shares but will not dilute shareholders' ownership percentage, except for minor adjustments due to fractional shares.
• The company is advancing its SIL-204B platform product through preclinical and clinical development, which requires significant capital.
• Failure to maintain the minimum bid price could deter potential investors and financing sources.
• Shareholders of record as of October 22, 2024, are entitled to vote at the meeting.
• The board of directors recommends voting for the reverse split proposal.

Sentiment

Score: 6

Explanation: The document is primarily informational, outlining the need for a reverse stock split. While the company expresses optimism about its clinical development programs, the necessity of the reverse split indicates underlying financial pressures. The sentiment is neutral to slightly positive, reflecting a proactive approach to address listing compliance.

Positives

• Maintaining the Nasdaq listing is crucial for attracting investors and securing funding.
• The reverse share split is intended to improve the company's share price and marketability.
• The company is actively advancing its SIL-204B platform product through clinical development.
• The reverse split will not dilute shareholders' ownership percentage.

Negatives

• The company's share price has been below $1.00 since September 16, 2024, indicating market concerns.
• The reverse share split may negatively impact the market for the company's ordinary shares.
• There is no guarantee that the share price will increase proportionately after the reverse split.
• The liquidity of the ordinary shares may be adversely affected by the reverse share split.

Risks

• The market price of the ordinary shares may not increase proportionately after the reverse share split.
• The liquidity of the ordinary shares may be adversely affected by the reverse share split.
• The company may experience extreme price volatility unrelated to its actual or expected operating performance.
• Broad market fluctuations and general economic and political conditions may adversely affect the market price of the ordinary shares.
• The company's ability to issue additional ordinary shares or other securities and obtain additional financing in the near future could be adversely affected.

Future Outlook

The company intends to use the remaining authorized shares for various purposes, including raising capital, providing equity incentives, and establishing strategic relationships. The board may implement the reverse share split promptly after shareholder approval.

Management Comments

• Our maintenance of a share price that is comfortably above the $1.00 minimum bid price level is a key strategic interest of ours, as it will assist us in raising capital to continue to support our preclinical studies and clinical trials.
• The Board believes that it is in the best interest of the Company and its shareholders and is hereby soliciting shareholder approval to effect a reverse share split of all the Companys issued and outstanding ordinary shares at a ratio of not less than 1-for-10 and not more than 1-for-20, inclusive.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low share prices. Many biotech companies, especially those in early stages of clinical development, may face similar challenges in maintaining share price compliance.

Comparison to Industry Standards

• Many small-cap biotech companies with limited revenue and high R&D expenses face challenges in maintaining a $1.00 minimum share price.
• Comparable companies that have implemented reverse stock splits to maintain Nasdaq listing include [hypothetical company A] and [hypothetical company B].
• The success of a reverse stock split in improving long-term share price performance varies widely and depends on the company's underlying fundamentals and market conditions.

Stakeholder Impact

• Shareholders may experience a change in the number of shares they own, but their percentage ownership will remain the same (except for minor adjustments due to fractional shares).
• Employees and officers holding equity awards will see adjustments to the number of shares and exercise prices.
• The company's ability to raise capital and fund its operations could be affected by the success of the reverse split.

Next Steps

• Shareholders will vote on the reverse split proposal at the extraordinary general meeting on November 12, 2024.
• The board of directors will determine the specific reverse split ratio based on market conditions prior to the meeting.
• If approved, the board will implement the reverse share split.

Key Dates

Keywords

reverse stock split, Nasdaq listing, minimum bid price, shareholder meeting, SIL-204B, compliance, funding, dilution, ordinary shares, Silexion Therapeutics